Dicarboxylic acid compound
It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. Solution: A compound represented by a general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, R 1 : a methyl group or the like, R 2 : a hydrogen atom or the like, R 3 : a hydrogen atom or the like, A: a cyclohexyl ring or the like, X: CH or the like, Y: CH or the like, Z: CH or the like, and n: 2 or the like].
1. A compound of general formula (I) or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof:
wherein each substituent is as defined below:
R 1 : a C1-6 alkyl group, a C1-6 alkoxy C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group,
R 2 : a hydrogen atom or a halogen group,
R 3 : a hydrogen atom, a halogen group, a halogeno C1-6 alkyl group, a halogeno C1-6 alkoxy group, a C2-5 saturated cyclic amino group, a C1-6 dialkylamino group, a C3-6 cycloalkyl C1-6 alkoxy group, or a C1-6 alkoxy group,
A: a C3-6 cycloalkyl ring,
X: CH or N,
Y: CH or N,
Z: CH or N, and
n: an integer selected from 1, 2, 3, and 4.
2. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 , wherein the compound of the general formula (I) is a compound of general formula (I′):
3. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 , wherein R 1 represents a methyl group, an ethyl group, a methoxyethyl group, a cyclopropyl group, or a cyclopropylmethyl group.
4. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according claim 1 , wherein R 2 represents a hydrogen atom, a chlorine atom, or a bromine atom.
5. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according claim 1 , wherein R 3 represents a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a 2,2,2-trifluoroethoxy group, a pyrrolidin-1-yl group, a piperidin-1-yl group, a diethylamino group, a cyclopropylmethoxy group, or a methoxy group.
6. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 , wherein A represents a cyclohexane ring.
7. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 , wherein X, Y, and Z each represent CH.
8. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 , wherein n is 2.
9. The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 , wherein:
R 1 is a methyl group, an ethyl group, a methoxyethyl group, a cyclopropyl group, or a cyclopropylmethyl group,
R 2 is a hydrogen atom, a chlorine atom, or a bromine atom,
R 3 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a 2,2,2-trifluoroethoxy group, a pyrrolidin-1-yl group, a piperidin-1-yl group, a diethylamino group, a cyclopropylmethoxy group, or a methoxy group,
A is a cyclohexane ring,
X is CH or N,
Y is CH or N,
Z is CH or N, and
n is 2 or 3.
10. The compound according to claim 1 , wherein the compound is selected from the following compound group:
or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.
11. The compound according to claim 1 , wherein the compound has the following formula:
or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.
12. The compound according to claim 1 , wherein the compound has the following formula:
or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.
13. The compound according to claim 1 , wherein the compound has the following formula:
or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.
14. The compound according to claim 1 , wherein the compound has the following formula:
or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof.
15. The pharmacologically acceptable salt of the compound according to claim 10 , which is a dipotassium salt or a hydrate thereof.
16. The pharmacologically acceptable salt of the compound according to claim 10 , which is a disodium salt or a hydrate thereof.
17. The pharmacologically acceptable salt according to claim 15 , which is a hydrate thereof.
18. A method for the prevention or treatment of hyperphosphatemia comprising administering to a patient a compound or pharmacologically acceptable salt thereof, or the hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 .
19. A pharmaceutical composition comprising the compound or pharmacologically acceptable salt thereof, or the hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 .
20. The pharmaceutical composition according to claim 19 , wherein administration to a patient of an effective amount of the pharmaceutical composition inhibits the uptake of phosphorus in the patient.